Menu Search
Equities

XOMA Royalty Corp

XOMA:NMQ

XOMA Royalty Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.80
  • Today's Change-1.05 / -3.52%
  • Shares traded26.86k
  • 1 Year change+81.25%
  • Beta0.9208
Data delayed at least 15 minutes, as of Sep 20 2024 19:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for XOMA Royalty Corp have a median target of 83.00, with a high estimate of 117.00 and a low estimate of 49.00. The median estimate represents a 178.06% increase from the last price of 29.85.
High292.0%117.00
Med178.1%83.00
Low64.2%49.00

Earnings history & estimates in USD

On Aug 13, 2024, XOMA Royalty Corp reported 2nd quarter 2024 earnings of 0.84 per share. This result exceeded the -0.270 consensus loss of the 3 analysts covering the company and outperformed last year's 2nd quarter results by 1.43.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-53.12%
XOMA Royalty Corp reported annual 2023 losses of -4.04 per share on Mar 08, 2024.
Average growth rate-61.39%
More ▼

Revenue history & estimates in USD

XOMA Corporation had 2nd quarter 2024 revenues of 11.09m. This bettered the 8.38m consensus of the 2 analysts covering the company. This was 2,437.76% above the prior year's 2nd quarter results.
Average growth rate+174.12%
XOMA Corporation had revenues for the full year 2023 of 4.76m. This was 21.06% below the prior year's results.
Average growth rate-3.86%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.